Keybank National Association OH lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 47.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,366 shares of the company’s stock after selling 46,732 shares during the period. Keybank National Association OH’s holdings in Henry Schein were worth $3,590,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the business. BlackRock Inc. increased its stake in shares of Henry Schein by 2.4% in the 1st quarter. BlackRock Inc. now owns 11,389,688 shares of the company’s stock valued at $684,635,000 after purchasing an additional 271,586 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Henry Schein by 22.1% in the 1st quarter. JPMorgan Chase & Co. now owns 2,426,917 shares of the company’s stock valued at $145,882,000 after purchasing an additional 439,922 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Henry Schein by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 2,105,314 shares of the company’s stock valued at $165,038,000 after purchasing an additional 161,542 shares during the last quarter. Northern Trust Corp increased its stake in shares of Henry Schein by 1.2% in the 1st quarter. Northern Trust Corp now owns 1,938,599 shares of the company’s stock valued at $116,529,000 after purchasing an additional 23,694 shares during the last quarter. Finally, Boston Partners bought a new position in shares of Henry Schein in the 1st quarter valued at $99,903,000.
Several brokerages have recently issued reports on HSIC. Leerink Swann lowered Henry Schein from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $75.00 to $70.00 in a research note on Wednesday, May 15th. They noted that the move was a valuation call. Cleveland Research reissued a “hold” rating on shares of Henry Schein in a report on Thursday, May 2nd. Barrington Research reissued a “buy” rating and set a $75.00 price objective on shares of Henry Schein in a report on Wednesday, August 7th. Craig Hallum reissued a “buy” rating and set a $77.00 price objective (up previously from $72.00) on shares of Henry Schein in a report on Wednesday, May 8th. Finally, BidaskClub downgraded Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $73.64.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 6th. The company reported $0.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.01. The firm had revenue of $2.45 billion for the quarter, compared to the consensus estimate of $2.48 billion. Henry Schein had a return on equity of 16.67% and a net margin of 4.18%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.04 EPS. On average, sell-side analysts predict that Henry Schein, Inc. will post 3.46 earnings per share for the current fiscal year.
In other Henry Schein news, Vice Chairman James P. Breslawski sold 6,856 shares of Henry Schein stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $60.17, for a total transaction of $412,525.52. Following the transaction, the insider now directly owns 249,046 shares of the company’s stock, valued at approximately $14,985,097.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Brons sold 1,758 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $70.96, for a total value of $124,747.68. Following the completion of the transaction, the director now directly owns 17,582 shares in the company, valued at $1,247,618.72. The disclosure for this sale can be found here. Insiders have sold a total of 56,524 shares of company stock worth $3,984,949 over the last ninety days. Company insiders own 1.06% of the company’s stock.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: What is operating income?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.